NATCO Pharma receives approval for Molnupiravir Capsules 200 mg for the treatment of Covid-19 in India

Natco Pharma Limited {NSE: NATCOPHARM; BSE: 524816) has received approval for Covid 19 drug Molnupiravir Capsules 200 mg. for Indian market, which will be sold under brand name MOLNUNAT . Molnupiravir is the first Covid drug authorized by Drugs Controller General {India) (DCGI) for the treatment of Covid 19 infection with Sp02>93% and who have high risk of progression of the disease including hospitalization or death. This capsule was earlier approved in United Kingdom and United States of America.

MOLNUNAT will be marketed by Natco and will be priced affordably. Molnupiravir is the first Covid drug available in Indian market with a minimal dosage duration of 5 days with promising viral clearance. Phase 3 trials of Molnupiravir has shown significant reduction in hospitalization of Covid 19 patients.

Contact:

Natco Pharma Limited

Pharma Division

Plot No: 19

Pharma City, Sidcul

Selaqui

Dehradun - 248 011

Uttarakhand

India

Phone: [phone]

Fax: [phone]

(C) 2021 Electronic News Publishing, source ENP Newswire